Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.023 ◽

2019 ◽

Vol 152 (2) ◽

pp. 416-425 ◽

Author(s):

Mary M. Mullen ◽

Lindsay M. Kuroki ◽

Premal H. Thaker

Keyword(s):

Ovarian Cancer ◽

Treatment Options ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive ◽

Novel Treatment

Download Full-text

Faculty Opinions recommendation of Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718040504.793483426 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive ◽

Docetaxel Chemotherapy

Download Full-text

Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

Therapy ◽

10.2217/thy.10.30 ◽

2010 ◽

Vol 7 (3) ◽

pp. 269-275 ◽

Author(s):

Maurie Markman

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Evidence Based ◽

Platinum Sensitive

Download Full-text

510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial

10.1136/ijgc-2020-esgo.146 ◽

2020 ◽

Author(s):

Douglas Cartwright ◽

Patricia Roxburgh ◽

Barbara Stanley ◽

Jennifer Brown ◽

Alistair Mclaren ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Wild Type ◽

Real World Data ◽

Platinum Sensitive

Download Full-text

Effects of PARP inhibitors therapy on the PFS and OS in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.630 ◽

2019 ◽

Vol 154 ◽

pp. 271

Author(s):

B.H. Min ◽

S.H. Yoon ◽

S.H. Shim

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Controlled Trials ◽

Randomized Controlled ◽

Platinum Sensitive

Download Full-text

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00681-8 ◽

2021 ◽

Vol 162 ◽

pp. S18

Author(s):

Qidan Huang ◽

Xiaohua Wu ◽

Jianqing Zhu ◽

Danqing Wang ◽

Jiaxin Yang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Subgroup Analysis ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Time To Progression ◽

Platinum Sensitive ◽

Platinum Based Chemotherapy

Download Full-text

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.07.081 ◽

2013 ◽

Vol 131 (1) ◽

pp. 169-173 ◽

Author(s):

Khursheed Anwer ◽

F. Joseph Kelly ◽

Christina Chu ◽

Jason G. Fewell ◽

Danny Lewis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive ◽

Docetaxel Chemotherapy

Download Full-text

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.024 ◽

2021 ◽

Vol 154 ◽

pp. 190-200

Author(s):

Angelina Tjokrowidjaja ◽

Michael Friedlander ◽

Sarah J. Lord ◽

Rebecca Asher ◽

Manuel Rodrigues ◽

...

Keyword(s):

Ovarian Cancer ◽

Progression Free Survival ◽

Recurrent Ovarian Cancer ◽

Brca Mutations ◽

Free Survival ◽

Platinum Sensitive ◽

Response To Chemotherapy

Download Full-text

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

Journal of Medical Economics ◽

10.1080/13696998.2018.1557199 ◽

2019 ◽

Vol 22 (2) ◽

pp. 187-195 ◽

Author(s):

Lei Wu ◽

Lixian Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Download Full-text

An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3546 ◽

2021 ◽

pp. clincanres.3546.2020

Author(s):

Ning Li ◽

Hualei Bu ◽

Jihong Liu ◽

Jianqing Zhu ◽

Qi Zhou ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase 2 ◽

Platinum Sensitive ◽

Download Full-text